Discover
COGT
Cogent Biosciences, Inc.
31.00
2 x 22.06
2 x 38.51
bid
ask
+
0.92
3.06%
2 @ 04:00 PM
31.00 +0.00 (0.00%)
| Ytd | -12.73% | |
| 1y | 91.48% |
29.90
day range
31.03
14.13
52 week range
42.84
| Open | 29.98 | Prev Close | 30.08 | Low | 29.90 | High | 31.03 | Mkt Cap | 5.38B |
| Vol | 2.52M | Avg Vol | 1.90M | EPS | -2.16 | P/E | N/A | Forward P/E | -27.88 |
| Beta | 0.31 | Short Ratio | 11.51 | Inst. Own | 115.22% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 35.25 | 200-d Avg | 36.20 | 1yr Est | 55.82 |
| Income Statement | |||
| Operating Expenses | 102.64M | ||
| Research and Development Expense | 70.81M | ||
| Selling, General and Administrative Expense | 31.83M | ||
| Operating Income | -102.64M | ||
| Interest Expense | 1.22M | ||
| Net Income | -96.40M | ||
| Net Income Common Stock | -96.40M | ||
| Net Income Common Stock (USD) | -96.40M | ||
| Consolidated Income | -96.40M | ||
| Earnings per Basic Share | -0.52 | ||
| Earnings per Basic Share (USD) | -0.52 | ||
| Earnings per Diluted Share | -0.52 | ||
| Earning Before Interest & Taxes (EBIT) | -95.19M | ||
| Earning Before Interest & Taxes (USD) | -95.19M | ||
| Weighted Average Shares | 171.01M | ||
| Weighted Average Shares Diluted | 171.01M | ||
| Balance Sheet | |||
| Cash and Equivalents | 181.59M | ||
| Cash and Equivalents (USD) | 181.59M | ||
| Investments | 611.13M | ||
| Investments Current | 611.13M | ||
| Current Assets | 804.82M | ||
| Property, Plant & Equipment Net | 27.37M | ||
| Total Assets | 834.55M | ||
| Debt Current | 1.49M | ||
| Total Debt | 244.26M | ||
| Current Liabilities | 59.30M | ||
| Debt Non-Current | 242.77M | ||
| Total Liabilities | 302.16M | ||
| Accumulated Retained Earnings (Deficit) | -1.38B | ||
| Accumulated Other Comprehensive Income | -770.00K | ||
| Shareholders Equity | 532.39M | ||
| Shareholders Equity (USD) | 532.39M | ||
| Assets Non-Current | 29.73M | ||
| Total Debt (USD) | 244.26M | ||
| Liabilities Non-Current | 242.86M | ||
| Trade and Non-Trade Payables | 7.49M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.37M | ||
| Net Cash Flow from Financing | 2.96M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -60.04M | ||
| Capital Expenditure | -370.00K | ||
| Net Cash Flow from Investing | 14.28M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 14.65M | ||
| Net Cash Flow from Operations | -77.27M | ||
| Share Based Compensation | 17.11M | ||